ANGLE PLC (LON:AGL) has highlighted the publication of independent research which further demonstrates the key advantages of its Parsortix system in the treatment of cancers.
The AIM-listed firm, a world leader in liquid biopsy, said the research published by the Heinrich Heine University of Duesseldorf in the International Journal of Molecular Science demonstrated the measurement of key proteins in breast cancer using Parsortix, which may advise therapy decisions in breast cancer treatment.
WATCH: ANGLE boss 'absolutely delighted' with results from pelvic mass study
The Dusseldorf study of 47 metastatic breast cancer patients showed that ANGLE’s Parsortix system harvests clinically relevant cancer cells for analysis that other systems miss, and also confirmed this by demonstrating that Parsortix can harvest such cells from the waste product of the leading antibody-based system.
ANGLE founder and chief executive, Andrew Newland, said: "These results published in a leading peer-reviewed journal are further demonstration of the key advantages of the Parsortix system.”
He added: “Our strategy of getting the Parsortix system widely used in leading cancer research centres is working well with customers driving growth in the body of evidence behind Parsortix."
The Duesseldorf university is a customer of ANGLE and its research work is independent of the company.